United States securities and exchange commission logo
November 15, 2022
Peter Huang, Esq.
Partner
Skadden, Arps, Slate, Meagher & Flom LLP
30/F, China World Office 2
No. 1, Jianguomenwai Avenue
Chaoyang District
Beijing 100004
People s Republic of China
Re: O2Micro
International Limited
Schedule 13E-3
filed by O2Micro International Limited et al.
Filed October 31,
2022
File No. 005-61085
Dear Peter Huang:
We have reviewed your filing and have the following comments. In
some of our
comments, we may ask you to provide us with information so we may better
understand your
disclosure.
Please respond to these comments by providing the requested
information or advise us as
soon as possible when you will respond. If you do not believe our
comments apply to your facts
and circumstances, please tell us why in your response.
After reviewing your response to these comments, we may have
additional comments.
All defined terms used herein have the same meaning as in the
preliminary statement.
Schedule 13E-3 Filed October 31, 2022
Background of the Merger, page 17
1. Refer to the first
paragraph on page 19. Disclosure in this paragraph indicates that
"Needham updated the
Special Committee on the status of its financial analyses, including
certain preliminary
valuation considerations, and discussed....the potential market check
and bidder outreach
process." We also note at the the May 17, 2022, June 7, 2022, and
July 21, 2022, meetings
Needham "updated the Special Committee on the progress of its
financial analyses."
Each presentation, discussion, or report held with or presented by the
financial advisor,
whether oral or written, is a separate report that requires a reasonably
detailed description
meeting the requirements of Item 1015 of Regulation M-A. This
Peter Huang, Esq.
Skadden, Arps, Slate, Meagher & Flom LLP
November 15, 2022
Page 2
requirement applies to both preliminary and final reports. If the
above statements
reference presentations made by Needham during the Special Committee's
evaluation of
the transaction, please supplement the disclosure to provide a
reasonable detailed
description of such meeting that satisfices the requirements of Item
1015 and file any
written materials, if applicable, as exhibits to the Schedule 13E-3
pursuant to Item 9 of
Schedule 13E-3 and Item 1016(c) of Regulation M-A.
Certain Financial Projections, page 33
2. Refer to the assumptions on page 34 marked with bullet points,
including without
limitation, references to:
implement strategic focus on LED television, mobile computing,
general lighting,
industrial and automtive
the gross margin as percentage will increase
research and development expense
selling, general and administrative
Please revise the disclosure to quantify all assumptions, where
practicable.
3. Please disclose the material factors that the Company expected to
negatively impact
growth prospects as discussed in (ii) on page 35.
Opinion of the Special Committee's Financial Advisor, page 36
4. The Discussion Materials filed as Exhibit (c)-(2) of Schedule 13E-3
should be
summarized in considerable detail in the proxy statement. See Item
1015(b)(6) of
Regulation M-A and Item 9 of Schedule 13E-3. Please revise this
section to disclose the
data underlying the results in each analysis prepared by Needham and
to show how that
information resulted in the multiples/values disclosed. As one example
only, disclose
the public companies valuation analysis starting on page 16.
We remind you that the filing persons are responsible for the accuracy
and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please direct any questions to Michael Killoy at 202-551-7576 or Daniel
Duchovny at
202-551-3619.
FirstName LastNamePeter Huang, Esq. Sincerely,
Comapany NameSkadden, Arps, Slate, Meagher & Flom LLP
Division of Corporation
Finance
November 15, 2022 Page 2 Office of Mergers &
Acquisitions
FirstName LastName